Literature DB >> 29959413

Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma.

Elias K Mai1, Thomas Hielscher2, Uta Bertsch3, Jana Schlenzka3, Hans J Salwender4, Markus Munder5, Christian Gerecke6, Ulrich Dührsen7, Peter Brossart8, Kai Neben9, Jens Hillengass3, Marc S Raab3, Maximilian Merz3, Marc-Andrea Baertsch3, Anna Jauch10, Dirk Hose3, Hans Martin11, Hans-Walter Lindemann12, Igor W Blau13, Christof Scheid14, Katja C Weisel15, Hartmut Goldschmidt3,16.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29959413     DOI： 10.1038/s41375-018-0195-9

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  3 in total

1.  Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma.

Authors:  Marc-Andrea Baertsch; Elias K Mai; Thomas Hielscher; Uta Bertsch; Hans J Salwender; Markus Munder; Stephan Fuhrmann; Ulrich Dührsen; Peter Brossart; Kai Neben; Jana Schlenzka; Christina Kunz; Marc S Raab; Jens Hillengaß; Anna Jauch; Anja Seckinger; Dirk Hose; Steffen Luntz; Pieter Sonneveld; Henk Lokhorst; Hans Martin; Martin Goerner; Martin Hoffmann; Hans-Walter Lindemann; Helga Bernhard; Igor W Blau; Christof Scheid; Britta Besemer; Katja C Weisel; Mathias Hänel; Jan Dürig; Hartmut Goldschmidt
Journal:  Blood Cancer J       Date:  2021-01-07       Impact factor: 11.037

Review 2.  The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma.

Authors:  Maximilian Merz; Tobias Dechow; Mithun Scheytt; Christian Schmidt; Bjoern Hackanson; Stefan Knop
Journal:  Ann Hematol       Date:  2020-04-16       Impact factor: 3.673

3.  Commentary: Lico A causes ER stress and apoptosis via up-regulating miR-144-3p in human lung cancer cell line H292.

Authors:  Yuanliang Yan; Zhicheng Gong; Zhijie Xu
Journal:  Biomed J       Date:  2019-01-02       Impact factor: 4.910
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.